anti-CD20

Ublituximab, Potential Relapsing MS Therapy, Up for FDA Approval

TG TherapeuticsĀ  has applied to the U.S. Food and Drug Administration (FDA) for approval ofĀ ublituximab, the companyā€™s investigational anti-CD20 monoclonal antibody therapy for relapsing forms of multiple sclerosis (RMS). Its application was based on data from the ULTIMATE 1 (NCT03277261) and ULTIMATE 2 (NCT03277248) Phase…

Anti-CD20 Therapies Show Similar Safety, Efficacy in RRMS

Anti-CD20 antibody therapies that target B-cells are highly effective for reducing the risk of relapses in people with relapsing-remitting multiple sclerosis (RRMS), a new analysis confirms. The analysis did not find any significant differences in efficacy or safety among the anti-CD20 therapies currently approved to treat RRMS, though…

#ECTRIMS2019 – Is Rituximab a Reasonable Option for MS Patients?

Editorā€™s note: This is the first story in a three-part report examining the question, ā€œIs rituximab a reasonable alternative treatment for MS?ā€, which was a topic discussed at this yearā€™s Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Here, we provide a synopsis of…

New Phase 2 Trial of a B-cell Antibody, TG-1101, to Treat Relapsing MS Getting Underway

TG TherapeuticsĀ recently announced the opening of a newĀ clinical trial evaluating TG-1101, its glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing-remitting multiple sclerosis (RRMS). The Phase 2 clinical trial, titled “A Placebo-Controlled Multi-Center Phase 2 Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients…

Leptomeningeal Inflammation May Offer New Treatment Targets In Progressive Forms of MS

Researchers at Johns Hopkins UniversityĀ in Baltimore presented keyĀ findings today, Feb. 19, concerningĀ the presence of contrast-enhancing lesions in later stages in the relapsing-remitting experimental autoimmune encephalitis (EAE) model. The presentation was made at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, which is ongoing through…